

A second UK Phase III anal cancer trial: a trial of chemoradiation and maintenance therapy for patients with anal cancer

Submission date 31/05/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 31/05/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/10/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00025090

Secondary identifying numbers

ACT II

Study information

Scientific Title

A second UK Phase III anal cancer trial: a trial of chemoradiation and maintenance therapy for patients with anal cancer

Acronym

ACT II

Study objectives

Following completion of ACT I the standard treatment for anal cancer is a combined modality treatment of radiotherapy, 5-Fluorouracil (5-FU) and mitomycin. However, the schedule used in ACT I may not be optimal and an improvement in outcome may be achieved by intensifying.

United Kingdom, European Organisation for Research and Treatment of Cancer (EORTC) and Intergroup pilot studies used three main approaches:

1. Modification of radiotherapy schedule
2. Changing the chemotherapy regimen
3. Additional courses of chemotherapy.

As a result, to avoid using split course radiotherapy a continuous course of radiotherapy (piloted in over 80 patients) will be used in this trial, cisplatin will be compared to mitomycin and patients will be randomised to maintenance chemotherapy.

Cisplatin was chosen as in combination with 5-FU it is active in advanced disease, it produces high Complete Remission (CR) rates in combination with radiotherapy and has activity in other squamous cell carcinomas.

Additional chemotherapy will be given after treatment as neo-adjuvant chemotherapy has not been shown to improve survival when given in combination with radiotherapy in other tumour sites. In addition the toxicity associated with it may impact on the timing of treatment and on the total dose of chemoradiation delivered.

Therefore, the objectives of this trial are as follows:

1. Whether Cisplatin or Mitomycin produces a higher CR rate post treatment
2. Whether Cisplatin or Mitomycin produces a higher grade four acute toxicity
3. Whether maintenance chemotherapy will improve recurrence-free survival

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Anal cancer

Interventions

Four treatment arms:

1. 5-Fluorouracil 1000 mg/m², days one to four and 29 to 32 by 24 hour continuous infusion and Mitomycin 12 mg/m², day one only, intravenous (iv) bolus and no maintenance therapy
2. 5-Fluorouracil 1000 mg/m², days one to four and 29 to 32 by 24 hour continuous infusion and Mitomycin 12 mg/m², day one only, iv bolus and maintenance therapy (CDDP)
3. 5-Fluorouracil 1000 mg/m², days one to four and 29 to 32 by 24 hour continuous infusion and Cisplatin 60 mg/m², days one and 29 by iv infusion and no maintenance therapy
4. 5-Fluorouracil 1000 mg/m², days one to four and 29 to 32 by 24 hour continuous infusion and Cisplatin 60 mg/m², days one and 29 by iv infusion and maintenance therapy (CDDP)

Maintenance therapy consists of:

Two courses 5-FU and Cisplatin, four weeks after the end of primary chemoradiation repeated after three weeks:

5-Fluorouracil 1000 mg/m², days one to four and Cisplatin 60 mg/m², day one by iv infusion

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

5-Fluorouracil, Mitomycin and Cisplatin

Primary outcome measure

1. CR rate (at six months):

1.1. 90% to detect an increase from 80% to 90%

1.2. 95% to detect an increase from 85% to 95%

2. Grade four toxicity: 95% to detect a doubling of the 11% Grade four acute toxicity reported in ACT I

3. Recurrence-free survival:

3.1. 80% to detect 11% difference (64% to 75%)

3.2. 99% to detect 16% difference (64% to 80%)

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/02/2001

Completion date

31/08/2007

Eligibility

Key inclusion criteria

1. Histological proof of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions)
2. Patients fit to receive platinum or mitomycin C based chemotherapy determined by:
 - 2.1. Adequate baseline renal function
 - 2.2. Acceptable haematological parameters
 - 2.3. Liver Function Tests (LFTs) within 2 x normal range
 - 2.4. Adequate cardiac function
 - 2.5. No serious uncontrolled medical conditions (particularly cardiovascular disease)
 - 2.6. Written informed consent

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

600

Key exclusion criteria

1. Anal cancer that has spread to another part of the body
2. Adenocarcinoma or muco-epidermoid anal cancer
3. Lymphoma or melanoma of the anal canal
4. Pre-cancerous cell changes (intraepithelial neoplasia) that have not developed into anal cancer
5. Had your cancer completely removed with an operation
6. Already had treatment for your anal cancer
7. Had radiotherapy to your pelvic area before
8. Had any other cancer in the past
9. Any other serious medical condition

Date of first enrolment

01/02/2001

Date of final enrolment

31/08/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123

Lincoln's Inn Fields

London

United Kingdom

WC2A 3PX

+44 (0)207 317 5186

kate.law@cancer.org.uk

Sponsor type

Charity

Website

<http://www.cancer.org.uk>

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes
Results article	results	01/08/2014		Yes	No
Results article	post-hoc analysis results	01/03/2017		Yes	No